Healthy men test new allergy drug copycat in Early-Stage trial
NCT ID NCT07246252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new version of the allergy drug omalizumab (called CMAB007) against the original drug (Xolair) in 114 healthy Chinese men. The goal was to see how the body processes each drug, check for side effects, and compare immune responses. No treatment was given for any disease; the study simply gathered data to support future development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui Central Hospital, Shanghai
Shanghai, China